Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This phase II trial studies how well avelumab with or without cetuximab work in treating
patients with skin squamous cell cancer that has spread to other places in the body.
Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread.
This phase III trial studies how well pembrolizumab works compared to standard of care
observation in treating patients with stage I-III Merkel cell cancer that has been completely
removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread.
This phase II trial studies how well encorafenib and binimetinib work before surgery in
treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph
nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission
tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to
encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and
CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib
may provide more information on melanoma over time.
This phase II trial investigates how well biomarkers on PET/CT imaging drive early
discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be
removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for
patients with unresectable melanoma. This trial is being done to determine if doctors can
safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers
seen on PET/CT imaging and tumor biopsy.
This phase II trial studies how pembrolizumab works before and after surgery in treating
patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery
may work better in treating melanoma.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management